Breaking Down Personalis: 5 Analysts Share Their Views
Across the recent three months, 5 analysts have shared their insights on Personalis (NASDAQ:PSNL), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated Personalis and provided 12-month price targets. The average target is $12.2, accompanied by a high estimate of $13.00 and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 10.91% increase from the previous average price target of $11.00.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Personalis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Raises | Buy | $12.00 | $10.00 |
| Mark Massaro | BTIG | Raises | Buy | $13.00 | $12.00 |
| Subbu Nambi | Guggenheim | Raises | Buy | $13.00 | $12.00 |
| Mark Massaro | BTIG | Maintains | Buy | $12.00 | $12.00 |
| Tejas Savant | Morgan Stanley | Raises | Equal-Weight | $11.00 | $9.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Personalis. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Personalis compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Personalis's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Personalis's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Personalis analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Personalis's Background
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Financial Milestones: Personalis's Journey
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Personalis faced challenges, resulting in a decline of approximately -43.62% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Personalis's net margin excels beyond industry benchmarks, reaching -149.38%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Personalis's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -11.95%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Personalis's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.63%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Personalis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.24.
The Core of Analyst Ratings: What Every Investor Should Know
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.